/ /

  • linkedin
  • Increase Font
  • Sharebar

    OCT + OCTA capable of imaging both structure and function

    Dual-modality system helps to visualize microvascular blood flow noninvasively quickly

    Take-home message: A new dual-modality imaging system adds optical coherence tomography angiography to conventional OCT to rapidly visualize blood flow in the retina and layers of choroidal neovascularization.

    Reviewed by Richard Rosen, MD

    New York—As drugs have been developed to treat choroidal neovascularization (CNV) by manipulating retinal thickness, it is increasingly important to monitor changes in the blood vessels at the microvascular level.

    A dual-modality optical coherence tomography (OCT) and OCT angiography (OCTA) system (AngioVue Imaging System, Optovue), which received FDA clearance in February, gives clinicians a three-dimensional picture of all the capillary beds of the retina that they can use to guide treatment decisions and personalize patient care.

    “This three-dimensional access to these different capillary beds empowers the clinician in ways that we couldn’t even imagine a few years ago,” said Richard Rosen, MD, professor and vice chairman, surgeon director, retina service chief, director of research, ophthalmology department, New York Eye and Ear Infirmary of Mount Sinai. Dr. Rosen has studied the technologies involved in OCTA in his lab and in collaboration with others and had access to the system as an investigational device through the infirmary’s institutional review board.

    “OCTA is like the ‘Swiss Army knife’ of vascular monitoring,” Dr. Rosen said. ”We really couldn’t look at the radial peripapillary capillary with fluorescein.

    “The only way we could visualize them prior to this technology was in the laboratory in histology slides or with adaptive optics imaging, but that’s not a practical clinical tool yet,” he said. “We couldn’t see the choriocapillaris very well, and that’s another vascular bed that we now have access to. And we really couldn’t differentiate the superficial deep or intermediate vascular beds.”

    With OCT angiography, surgeons have a more complete appreciation of these capillary beds. Physicians can see extraordinary details of different types of choroidal neovascularization, Dr. Rosen noted.

    “Retinal physicians are now trying to figure out how to better classify choroidal neovascularization using this technology, in order to predict which patients require treatment, how to judge response to treatment, and how to determine membrane stability, which may not require re-treatment,” he said.

    More about OCTA

    OCTA is a noninvasive, dyeless technique that uses light rays to form detailed three-dimensional images of the retina and visualize the presence or absence of flow in the blood vessels.

    “OCTA adds a functional layer of information on top of the anatomic information from the regular OCT,” said Tony Ko, PhD, vice president of research and development at Optovue. “There are things you can see with this technology that you can’t with previous techniques. Looking directly at the vessels with OCTA rather than using standard OCT to view a marker or sign of neovascularization could change the way patients with diabetic retinopathy or choroidal neovascularization are treated.”

    The system can produce an image of a small segment—3 by 3 mm or 6 by 6mm—of the central macula or optic nerve or piece together multiple small segments to create a larger montage.

    Researchers have been exploring various approaches to OCTA for more than a decade. Originally it was a research tool and was not ready for commercialization until obstacles to clinical use such as long visualization times were overcome, Dr. Ko said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results